Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | ESPL1 | Q14674 | 1/20 | 0.45 |
| ▸ | TTR | P02766 | 3/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SNCA | P37840 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30041049 | 0.92 | GPR35 (0.47) | GPR35ALDH1A1TDP1ATMESPL1 | |
| SCHEMBL21835253 | 0.92 | GPR35 (0.47) | GPR35ALDH1A1TDP1ATMESPL1 | |
| SCHEMBL10342981 | 0.85 | GPR35 (0.47) | GPR35ALDH1A1TDP1ATMTTR | |
| SCHEMBL12593915 | 0.84 | TDP1 (0.52) | GPR35ALDH1A1TDP1ATMESPL1 | |
| SCHEMBL28892661 | 0.84 | SNCA (0.55) | GPR35ALDH1A1TDP1ATMESPL1 | |
| SCHEMBL4368022 | 0.84 | GPR35 (0.54) | GPR35ALDH1A1TDP1TTRHIF1A | |
| SCHEMBL10266188 | 0.82 | GPR35 (0.52) | GPR35ALDH1A1TDP1TTRHIF1A | |
| SCHEMBL187542 | 0.82 | TDP1 (0.50) | GPR35ALDH1A1TDP1ATMESPL1 | |
| SCHEMBL397387 | 0.82 | ATM (0.50) | GPR35ALDH1A1TDP1ATMESPL1 | |
| SCHEMBL29805163 | 0.82 | TDP1 (0.50) | GPR35ALDH1A1TDP1ATMESPL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0307777-B1 | 2-METHYL-4-FLUORO-PHENOLS AND PROCESS FOR THEIR PREPARATION | BAYER AG (DE) | 1993-01-07 | — | — | EP | claimed |
| US-4885388-A | CHEMICAL INTERMEDIATES FOR THE PREPARATION OF HERBICIDES AND PLANT GROWTH REGULATORS | BAYER AKTIENGESELLSCHAFT (DE) | 1989-12-05 | — | — | US | claimed |
| EP-0307777-A2 | 2-Methyl-4-fluoro-phenols and process for their preparation | BAYER AG (DE) | 1989-03-22 | — | — | EP | claimed |
| JP-1113348-A | — | — | None | — | — | JP | disclosed |
| US-12391663-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-19 | — | — | US | disclosed |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-08-08 | — | — | US | disclosed |
| US-20240083869-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-03-14 | — | — | US | disclosed |
| US-11912682-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| CN-117242060-A | Isoindolinone compounds | 蒙特罗萨医疗公司 | 2023-12-15 | — | — | CN | disclosed |
| EP-4277901-A1 | ISOINDOLINONE COMPOUNDS | Monte Rosa Therapeutics, Inc. (US) | 2023-11-22 | — | — | EP | disclosed |
| EP-4278014-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | Monte Rosa Therapeutics, Inc. (US) | 2023-11-22 | — | — | EP | disclosed |
| WO-1997030035-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | ZENECA LIMITED (GB) | 1997-08-21 | — | — | WO | disclosed |
| WO-1997022596-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-06-26 | — | — | WO | disclosed |
| EP-0307777-B1 | 2-METHYL-4-FLUORO-PHENOLS AND PROCESS FOR THEIR PREPARATION | BAYER AG (DE) | 1993-01-07 | — | — | EP | disclosed |
| EP-0382034-A1 | N-aryl-nitrogenated heterocycles | BAYER AG (DE) | 1990-08-16 | — | — | EP | disclosed |
| EP-0363585-A1 | N-aryl nitrogen heterocycles | BAYER AG (DE) | 1990-04-18 | — | — | EP | disclosed |
| US-4885388-A | CHEMICAL INTERMEDIATES FOR THE PREPARATION OF HERBICIDES AND PLANT GROWTH REGULATORS | BAYER AKTIENGESELLSCHAFT (DE) | 1989-12-05 | — | — | US | disclosed |
| JP-H01113348-A | NEW 2-METHYL-4-FLUORO-PHENOL AND ITS PREPARATION | BAYER AG | 1989-05-02 | — | — | JP | disclosed |
| EP-0308702-A2 | N-aryl-nitrogen heterocycles | BAYER AG (DE) | 1989-03-29 | — | — | EP | disclosed |
| EP-0307777-A2 | 2-Methyl-4-fluoro-phenols and process for their preparation | BAYER AG (DE) | 1989-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12391663-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | GPR35 3797/4885ALDH1A1 1142/4885TDP1 4627/4885 |
| US-20240083869-A1 | ISOINDOLINONE COMPOUNDS | CYP4F2, AOC2, AOC3 | GPR35 3797/4885ALDH1A1 1142/4885TDP1 4627/4885 |
| US-11912682-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | GPR35 3797/4885ALDH1A1 1142/4885TDP1 4627/4885 |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MYC, MYCBP, GSPT1 | GPR35 2597/4885ALDH1A1 4276/4885TDP1 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.